EvolutionRMS: A Phase III Randomized Controlled Study of Evobrutinib to Evaluate Efficacy and Safety

The EvolutionRMS study is looking at a medication called evobrutinib for people with relapsing multiple sclerosis (RMS) with relapses. This investigational medication will be compared to teriflunomide, a medication that is already being used to treat RMS, during a 2-year-long study.

VERISMO: An Observational Study of MS Patients - Now Enrolling

Ocrelizumab has been shown to be an effective treatment option for patients with MS, but the FDA has requested that a study be undertaken to determine the long-term health effects of ocrelizumab.This 10-year-long study will observe 4,000 patients in the US and Germany who have newly started ocrelizumab or another MS disease modifying therapy. Participation in this observational study does not require any special visits to MGH; instead, the research team will follow participants through the electronic medical record for up to 5 years. If you are interested in participating, please contact Dylan Rice at drice2@mgh.harvard.edu or 617-643-2947.

MAMBO: Treating Post-Stroke Disability in Tanzania with Fluoxetine

Fluoxetine has shown promise as a pharmacological treatment for motor recovery after stroke, but its use for such indications has not been tested in the low-income countries that bear the greatest burden of stroke disability and mortality. In the MAMBO (Kiswahili for “Hello”) clinical trial, we will test the safety and tolerability of fluoxetine for post-stroke motor recovery in Tanzania. We will also investigate post-stroke dementia in Tanzanian patients. Funded by the National Institutes of Health.

Past Projects

Electronic Pill Bottle Monitoring to Promote Medication Adherence in Multiple Sclerosis

Keeping track of whether you've taken your medications can be difficult, but in diseases like Multiple Sclerosis (MS) taking a medication regularly can have a great impact on the course of the disease. We are undertaking a study to determine if electronic pill bottles can help patients with MS remember to take their oral disease modifying therapies more regularly. Enrollment for this study is now complete. Please contact Dylan Rice (drice2@mgh.harvard.edu or 617-643-2947) if you are interested in hearing more about this project.

Smartphone EEG in Bhutan and Guinea

The group is conducting a clinical study to test the feasibility of using a smartphone-based electroencephalograph (EEG) system to diagnose patients with epilepsy in Bhutan, a small, land-locked country between China and India, and Guinea, a country on the Atlantic coast of Africa bordered by Mali and Sierra Leone. Funded by the Charles Hood Foundation, the Harvard University Asia Center and the National Institutes of Health (NIH).

Resources for the Smartphone EEG project:

Light Therapy for Fatigue in Multiple Sclerosis

Fatigue is the most commonly reported symptom among people living with MS, and more than a quarter report fatigue as their most disabling symptom. We are conducting a double-blind, placebo-controlled clinical trial to determine whether light therapy can be used as a treatment for MS-related fatigue

Resources for the multiple sclerosis light therapy study:

A Global Atlas of NMO Diagnosis and Treatment Practices

Neuromyelitis optica (NMO) is a demyelinating disease of the optica nerve and spinal cord. Despite recent advances in the treatment and diagnosis of NMO, little is known about the global availability of diagnostic tests and medications for the disease. We surveyed physicians from over 120 different countries on the availability, affordability, and accessibility of a variety of clinical options to diagnose and treat neuromyelitis optica (NMO).

This study was sponsored by ZoomRX and the Sumaira Foundation.

Platelet Signatures in Multiple Sclerosis

Platelet Signatures in Multiple Sclerosis When faced with clinical symptoms of multiple sclerosis (MS), a neurodegenerative condition, patients and physicians can be uncertain of how to proceed. There are multiple diseases that mimic the symptoms of MS; some of them require special treatment and care.

A blood test for MS could allow physicians to more confidently direct the care of their patients; unfortunately, no such blood test currently exists. But there is evidence that platelet RNA signatures may change in MS patients. We are analyzing the blood of MS patients, healthy patients, and patients with MS- mimicking diseases to determine whether there is a platelet-based RNA signature that can help confirm diagnosis of multiple sclerosis.


See complete list of publications on PubMed.